Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Net Cash Flow: 2017-2025

Historic Net Cash Flow for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to -$146,000.

  • Aclaris Therapeutics' Net Cash Flow fell 100.59% to -$146,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.4 million, marking a year-over-year decrease of 360.07%. This contributed to the annual value of -$15.3 million for FY2024, which is 183.53% down from last year.
  • Per Aclaris Therapeutics' latest filing, its Net Cash Flow stood at -$146,000 for Q3 2025, which was up 97.05% from -$5.0 million recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year Net Cash Flow high stood at $78.2 million for Q2 2021, and its period low was -$59.8 million during Q3 2021.
  • Its 3-year average for Net Cash Flow is -$4.3 million, with a median of -$555,000 in 2023.
  • Its Net Cash Flow has fluctuated over the past 5 years, first spiked by 465.24% in 2021, then crashed by 2,854.30% in 2024.
  • Over the past 5 years, Aclaris Therapeutics' Net Cash Flow (Quarterly) stood at -$26.3 million in 2021, then surged by 37.62% to -$16.4 million in 2022, then skyrocketed by 105.12% to $838,000 in 2023, then slumped by 2,854.30% to -$23.1 million in 2024, then crashed by 100.59% to -$146,000 in 2025.
  • Its Net Cash Flow was -$146,000 in Q3 2025, compared to -$5.0 million in Q2 2025 and $5.8 million in Q1 2025.